Synthetic spadin-derived heptapeptide (TREK-1 inhibitor)
A seven-amino-acid peptide engineered from spadin that is being researched as a fast-acting antidepressant candidate.
| Class / type | Synthetic spadin-derived heptapeptide (TREK-1 inhibitor) |
|---|---|
| Category | Cognitive & Nootropic |
| Status (Jul 2026) | Research use only |
It blocks the TREK-1 two-pore-domain potassium channel in mood- and cognition-related brain regions, which increases neuronal excitability and is associated with enhanced neurogenesis and rapid antidepressant-like effects.
Preclinical research into depression, mood disorders, and neurogenesis.
In rodent models it produces rapid antidepressant-like effects with improved potency, stability, and duration compared with spadin.
No human clinical trials; whether TREK-1 blockade produces real antidepressant effects in people is unproven; long-term safety unknown; sold only as an unregulated research chemical.
Some experimenters report mood and motivation benefits, but reports are anecdotal and unverified.
NOT FDA-approved for any indication; it is an unapproved research chemical sold for laboratory use only and not authorized for human use.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.